“Medicare doesn't need to cover Ozempic. Medicare needs to take Ozempic.” Cato’s @mfcannon told @AJEnglish that the real path to affordable GLP-1 drugs isn’t government subsidies, but eliminating cost-increasing regulation.
— Cato Institute (@CatoInstitute) August 6, 2026
Let price competition work, and people won't need… pic.twitter.com/D34lR4D6cx
